The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 201-209

  Casarosa, Paola ^a   Kiechle, Tobias ^a   Sieger, Peter ^a   Pieper, Michael ^a   Gantner, Florian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACLIDINIUM BROMIDE; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; LIGAND; MUSCARINE; MUSCARINIC RECEPTOR; OXOTREMORINE; PILOCARPINE; PIRENZEPINE; SCOPOLAMINE; TIOTROPIUM BROMIDE;

ANIMAL CELL; ARTICLE; ASSAY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION (PARAMETERS); CONFORMATION; DISSOCIATION; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; UPREGULATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG INVERSE AGONISM; GENES, REPORTER; HUMANS; LUCIFERASES; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; PROTEIN CONFORMATION; RECEPTOR, MUSCARINIC M3; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 77949722643     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.163188     Document Type: Article

References (29)

1. Angel P and Karin M (1991) The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta Rev Cancer 1072:129-157.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100:11406-11411.
3. Barnes PJ (2004a) Distribution of receptor targets in the lung. Proc Am Thorac Soc 1:345-351.
4. Barnes PJ (2004b) The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 117 (Suppl 12A):24S-32S.
5. Burstein ES, Spalding TA, Brauner-Osborne H, and Brann MR (1995) Constitutive activation of muscarinic receptors by the G protein Gq. FEBS Lett 363:261-263.
6. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, and Pieper M (2009) Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 330:660-668.
7. Chevalier B, Mansier P, Teiger E, Callen-el AF, and Swynghedauw B (1991) Alterations in beta adrenergic and muscarinic receptors in aged rat heart. Effects of chronic administration of propranolol and atropine. Mech Ageing Dev 60:215-224.
8. Chiba Y, Murata M, Ushikubo H, Yoshikawa Y, Saitoh A, Sakai H, Kamei J, and Misawa M (2005) Effect of cigarette smoke exposure in vivo on bronchial smooth muscle contractility in vitro in rats. Am J Respir Cell Mol Biol 33:574-581.
9. De Deurwaerdére P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241.
10. de Ligt RA, Kourounakis AP, and IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
11. Dowling MR, Willets JM, Budd DC, Charlton SJ, Nahorski SR, and Challiss RA (2006) A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J Pharmacol Exp Ther 317:1134-1142.
12. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276: 24433-24436.
13. qα protein expression and function in human airway smooth muscle cells. Am J Physiol 276:L405-L411.
14. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
15. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
16. Kenakin T (2004) Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
17. Leff P (1995) Inverse agonism: theory and practice. Trends Pharmacol Sci 16:256.
18. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
19. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, and Arrang JM (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408:860-864.
20. Profita M, Bonanno A, Siena L, Bruno A, Ferraro M, Montalbano AM, Albano GD, Riccobono L, Casarosa P, Pieper MP, et al. (2009) Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 329:753-763.
21. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, and Vignola AM (2005) Muscarinic receptors, leukotriene B4 production, and neutrophilic inflammation in COPD patients. Allergy 60:1361-1369.
22. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
23. Strange PG (2002) Mechanisms of inverse agonism at G protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
24. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, and Decramer M (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554.
25. Wall SJ, Yasuda RP, Li M, Ciesla W, and Wolfe BB (1992) Differential regulation of subtypes m1-m5 of muscarinic receptors in forebrain by chronic atropine administration. J Pharmacol Exp Ther 262:584-588.
26. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996) The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. J Theor Biol 181:381-397.
27. Wess J (1993) Molecular basis of muscarinic acetylcholine receptor function. Trends Pharmacol Sci 14:308-313.
28. Witt-Enderby PA, Yamamura HI, Halonen M, Lai J, Palmer JD, and Bloom JW (1995) Regulation of airway muscarinic cholinergic receptor subtypes by chronic anticholinergic treatment. Mol Pharmacol 47:485-490.
29. Zeng FY, McLean AJ, Milligan G, Lerner M, Chalmers DT, and Behan DP (2003) Ligand-specific up-regulation of a Renilla reniformis luciferase-tagged, structurally unstable muscarinic M3 chimeric G protein-coupled receptor. Mol Pharmacol 64:1474-1484.